[Form 4] Shattuck Labs, Inc. Insider Trading Activity
Dr. Mona Ashiya, a director of Shattuck Labs, Inc. (STTK), was granted a stock option on 08/28/2025 allowing purchase of 66,300 shares of common stock at a $0.99 exercise price. The option vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, is exercisable beginning on those vesting dates, and expires on August 28, 2035. The Form 4 reports 66,300 derivative securities beneficially owned following the transaction, filed by one reporting person and signed by an attorney-in-fact on 09/02/2025. An agreement requires the Reporting Person to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for allocation to OrbiMed Private Investments IX, LP.
La Dott.ssa Mona Ashiya, direttrice di Shattuck Labs, Inc. (STTK), ha ricevuto in data 28/08/2025 un鈥檕pzione su azioni che le consente di acquistare 66.300 azioni ordinarie a un prezzo di esercizio di $0,99. L鈥檕pzione matura in tre rate annuali uguali nei primi tre anniversari del 28 agosto 2025, pu貌 essere esercitata a partire da ciascuna di tali date di maturazione e scade il 28 agosto 2035. Il Modulo 4, depositato il 02/09/2025 e firmato per procura, riporta 66.300 strumenti derivati detenuti a titolo beneficiario dopo l鈥檕perazione e indica un unico soggetto segnalante. Un accordo impone al Reporting Person di trasferire eventuali titoli o benefici economici derivanti da questi premi a OrbiMed Advisors LLC e OrbiMed Capital GP IX LLC per l鈥檃llocazione a OrbiMed Private Investments IX, LP.
La Dra. Mona Ashiya, directora de Shattuck Labs, Inc. (STTK), recibi贸 el 28/08/2025 una opci贸n sobre acciones que le permite comprar 66.300 acciones ordinarias a un precio de ejercicio de $0,99. La opci贸n vence en tres cuotas anuales iguales en cada uno de los tres primeros aniversarios del 28 de agosto de 2025, puede ejercerse a partir de esas fechas de adquisici贸n y caduca el 28 de agosto de 2035. El Formulario 4, presentado el 02/09/2025 y firmado por un apoderado, informa de 66.300 valores derivados de titularidad beneficiaria tras la operaci贸n y fue presentado por una sola persona informante. Un acuerdo exige que la persona informante transfiera cualquier valor o beneficio econ贸mico procedente de estos premios a OrbiMed Advisors LLC y OrbiMed Capital GP IX LLC para su asignaci贸n a OrbiMed Private Investments IX, LP.
靸ろ劚 霝╈姢(Shattuck Labs, Inc., STTK) 鞚挫偓鞚� 氇倶 鞎勳嫓鞎� 氚曥偓電� 2025雲� 8鞗� 28鞚检棎 氤错喌欤� 66,300欤茧ゼ 欤茧嫻 $0.99鞚� 頄夓偓臧�瓴╈溂搿� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 鞓奠厴鞚� 2025雲� 8鞗� 28鞚检潉 鞁滌瀾鞙茧 觳� 3臧� 旮半厫鞚检棎 瓯胳硱 鞐瓣皠 霃欖澕 牍勳湪搿� 靹� 彀鞐� 瓯胳硱 臧�靻嶋悩氅�, 臧� 臧�靻嶌澕鞐� 頄夓偓頃� 靾� 鞛堦碃 2035雲� 8鞗� 28鞚检棎 毵岆霅╇媹雼�. 2025雲� 9鞗� 2鞚检棎 鞝滌稖霅� Form 4鞐愲姅 瓯半灅 鞚错泟鞐� 66,300臧滌潣 韺岇儩歃濌秾鞚� 靾橃澋鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 頃橂倶鞚� 氤搓碃鞛愱皜 鞝滌稖頃橁碃 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟. 頃� 瓿勳暯鞐� 霐半澕 氤搓碃鞛愲姅 鞚� 氤挫儊鞙茧 氚滌儩頃� 歃濌秾 霕愲姅 瓴届牅鞝� 鞚挫澋鞚� OrbiMed Advisors LLC 氚� OrbiMed Capital GP IX LLC搿� 鞚挫爠頃橃棳 OrbiMed Private Investments IX, LP鞐� 氚半秳頃挫暭 頃╇媹雼�.
Le Dr Mona Ashiya, administratrice de Shattuck Labs, Inc. (STTK), s鈥檈st vu accorder le 28/08/2025 une option d鈥檃chat lui permettant d鈥檃cqu茅rir 66 300 actions ordinaires au prix d鈥檈xercice de 0,99 $. L鈥檕ption acquiert des droits en trois versements annuels 茅gaux lors des trois premiers anniversaires du 28 ao没t 2025, est exer莽able 脿 compter de ces dates d鈥檃cquisition et expire le 28 ao没t 2035. Le formulaire 4, d茅pos茅 le 02/09/2025 et sign茅 par un mandataire, indique 66 300 titres d茅riv茅s d茅tenus 脿 titre b茅n茅ficiaire apr猫s l鈥檕p茅ration et a 茅t茅 d茅pos茅 par une seule personne d茅clarente. Un accord oblige la personne d茅clarente 脿 transf茅rer tout titre ou avantage 茅conomique r茅sultant de ces attributions 脿 OrbiMed Advisors LLC et OrbiMed Capital GP IX LLC pour affectation 脿 OrbiMed Private Investments IX, LP.
Dr. Mona Ashiya, Direktorin von Shattuck Labs, Inc. (STTK), erhielt am 28.08.2025 eine Aktienoption, die ihr den Kauf von 66.300 Stammaktien zu einem Aus眉bungspreis von $0,99 erlaubt. Die Option wird in drei gleichen j盲hrlichen Raten zu den ersten drei Jahrestagen des 28. August 2025 unverfallbar, ist ab diesen Vesting-Daten aus眉bbar und verf盲llt am 28. August 2035. Das am 02.09.2025 eingereichte Formular 4, unterzeichnet von einem Bevollm盲chtigten, weist nach der Transaktion 66.300 derivativen Wertpapiere als wirtschaftlich gehalten aus und wurde von einer meldenden Person eingereicht. Einer Vereinbarung zufolge muss die meldende Person s盲mtliche aus diesen Zuwendungen hervorgehenden Wertpapiere oder wirtschaftlichen Vorteile an OrbiMed Advisors LLC und OrbiMed Capital GP IX LLC zur Zuordnung an OrbiMed Private Investments IX, LP 眉bertragen.
- Option grant disclosed: 66,300鈥憇hare stock option awarded on 08/28/2025 with a clearly stated $0.99 exercise price.
- Clear vesting schedule: Option vests in three equal annual installments on each of the first three anniversaries of 08/28/2025.
- Full expiry date provided: Option expires on 08/28/2035, giving a defined exercise window.
- Transfer obligation disclosed: Reporting Person is required to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for provision to OrbiMed Private Investments IX, LP.
- Beneficial ownership complexity: Although 66,300 derivative securities are reported as beneficially owned following the grant, the transfer arrangement affects direct economic control.
Insights
TL;DR: Director granted a time鈥慴ased option for 66,300 shares with an explicit transfer arrangement to OrbiMed entities.
The Form 4 discloses a time鈥慴ased stock option awarded on 08/28/2025 with a $0.99 exercise price covering 66,300 shares and a ten鈥憏ear term to expiry on 08/28/2035. Vesting is set in three equal annual installments beginning one year from grant, which ties realization of economic benefit to continued service. The filing also documents a contractual obligation to transfer any issued shares or economic proceeds to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for ultimate provision to OrbiMed Private Investments IX, LP, indicating the reporter does not retain unilateral control of proceeds. The report was executed by an attorney鈥慽n鈥慺act and filed as a single reporting person Form 4.
TL;DR: Standard time鈥慴ased option grant with multi鈥憏ear vesting and an explicit third鈥憄arty transfer arrangement.
The disclosed award is structured as a ten鈥憏ear stock option exercisable into 66,300 shares at $0.99, with vesting in three equal annual tranches beginning 08/28/2026. The filing clearly states the option award and the mechanics of vesting and expiry. The obligation to transfer any shares or economic benefit to specified OrbiMed entities is explicitly documented, which affects beneficial ownership and economic receipt despite the option being reported as beneficially owned on a direct basis following the grant. All key dates, quantities, and the transfer agreement are provided in the filing.
La Dott.ssa Mona Ashiya, direttrice di Shattuck Labs, Inc. (STTK), ha ricevuto in data 28/08/2025 un鈥檕pzione su azioni che le consente di acquistare 66.300 azioni ordinarie a un prezzo di esercizio di $0,99. L鈥檕pzione matura in tre rate annuali uguali nei primi tre anniversari del 28 agosto 2025, pu貌 essere esercitata a partire da ciascuna di tali date di maturazione e scade il 28 agosto 2035. Il Modulo 4, depositato il 02/09/2025 e firmato per procura, riporta 66.300 strumenti derivati detenuti a titolo beneficiario dopo l鈥檕perazione e indica un unico soggetto segnalante. Un accordo impone al Reporting Person di trasferire eventuali titoli o benefici economici derivanti da questi premi a OrbiMed Advisors LLC e OrbiMed Capital GP IX LLC per l鈥檃llocazione a OrbiMed Private Investments IX, LP.
La Dra. Mona Ashiya, directora de Shattuck Labs, Inc. (STTK), recibi贸 el 28/08/2025 una opci贸n sobre acciones que le permite comprar 66.300 acciones ordinarias a un precio de ejercicio de $0,99. La opci贸n vence en tres cuotas anuales iguales en cada uno de los tres primeros aniversarios del 28 de agosto de 2025, puede ejercerse a partir de esas fechas de adquisici贸n y caduca el 28 de agosto de 2035. El Formulario 4, presentado el 02/09/2025 y firmado por un apoderado, informa de 66.300 valores derivados de titularidad beneficiaria tras la operaci贸n y fue presentado por una sola persona informante. Un acuerdo exige que la persona informante transfiera cualquier valor o beneficio econ贸mico procedente de estos premios a OrbiMed Advisors LLC y OrbiMed Capital GP IX LLC para su asignaci贸n a OrbiMed Private Investments IX, LP.
靸ろ劚 霝╈姢(Shattuck Labs, Inc., STTK) 鞚挫偓鞚� 氇倶 鞎勳嫓鞎� 氚曥偓電� 2025雲� 8鞗� 28鞚检棎 氤错喌欤� 66,300欤茧ゼ 欤茧嫻 $0.99鞚� 頄夓偓臧�瓴╈溂搿� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 鞓奠厴鞚� 2025雲� 8鞗� 28鞚检潉 鞁滌瀾鞙茧 觳� 3臧� 旮半厫鞚检棎 瓯胳硱 鞐瓣皠 霃欖澕 牍勳湪搿� 靹� 彀鞐� 瓯胳硱 臧�靻嶋悩氅�, 臧� 臧�靻嶌澕鞐� 頄夓偓頃� 靾� 鞛堦碃 2035雲� 8鞗� 28鞚检棎 毵岆霅╇媹雼�. 2025雲� 9鞗� 2鞚检棎 鞝滌稖霅� Form 4鞐愲姅 瓯半灅 鞚错泟鞐� 66,300臧滌潣 韺岇儩歃濌秾鞚� 靾橃澋鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 頃橂倶鞚� 氤搓碃鞛愱皜 鞝滌稖頃橁碃 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟. 頃� 瓿勳暯鞐� 霐半澕 氤搓碃鞛愲姅 鞚� 氤挫儊鞙茧 氚滌儩頃� 歃濌秾 霕愲姅 瓴届牅鞝� 鞚挫澋鞚� OrbiMed Advisors LLC 氚� OrbiMed Capital GP IX LLC搿� 鞚挫爠頃橃棳 OrbiMed Private Investments IX, LP鞐� 氚半秳頃挫暭 頃╇媹雼�.
Le Dr Mona Ashiya, administratrice de Shattuck Labs, Inc. (STTK), s鈥檈st vu accorder le 28/08/2025 une option d鈥檃chat lui permettant d鈥檃cqu茅rir 66 300 actions ordinaires au prix d鈥檈xercice de 0,99 $. L鈥檕ption acquiert des droits en trois versements annuels 茅gaux lors des trois premiers anniversaires du 28 ao没t 2025, est exer莽able 脿 compter de ces dates d鈥檃cquisition et expire le 28 ao没t 2035. Le formulaire 4, d茅pos茅 le 02/09/2025 et sign茅 par un mandataire, indique 66 300 titres d茅riv茅s d茅tenus 脿 titre b茅n茅ficiaire apr猫s l鈥檕p茅ration et a 茅t茅 d茅pos茅 par une seule personne d茅clarente. Un accord oblige la personne d茅clarente 脿 transf茅rer tout titre ou avantage 茅conomique r茅sultant de ces attributions 脿 OrbiMed Advisors LLC et OrbiMed Capital GP IX LLC pour affectation 脿 OrbiMed Private Investments IX, LP.
Dr. Mona Ashiya, Direktorin von Shattuck Labs, Inc. (STTK), erhielt am 28.08.2025 eine Aktienoption, die ihr den Kauf von 66.300 Stammaktien zu einem Aus眉bungspreis von $0,99 erlaubt. Die Option wird in drei gleichen j盲hrlichen Raten zu den ersten drei Jahrestagen des 28. August 2025 unverfallbar, ist ab diesen Vesting-Daten aus眉bbar und verf盲llt am 28. August 2035. Das am 02.09.2025 eingereichte Formular 4, unterzeichnet von einem Bevollm盲chtigten, weist nach der Transaktion 66.300 derivativen Wertpapiere als wirtschaftlich gehalten aus und wurde von einer meldenden Person eingereicht. Einer Vereinbarung zufolge muss die meldende Person s盲mtliche aus diesen Zuwendungen hervorgehenden Wertpapiere oder wirtschaftlichen Vorteile an OrbiMed Advisors LLC und OrbiMed Capital GP IX LLC zur Zuordnung an OrbiMed Private Investments IX, LP 眉bertragen.
FAQ
What did Dr. Mona Ashiya report on the Form 4 for STTK?
What is the vesting schedule and expiration for the option in the STTK Form 4?
Does the Form 4 indicate any transfer or third鈥憄arty arrangement?
When was the Form 4 filed and who signed it?
How many derivative securities are reported as beneficially owned after the transaction?
